Cargando…
Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment
Urothelial bladder cancer (BLCA) is a common internal malignancy with a poor prognosis. The re-programming of lipid metabolism is necessary for cancer cell growth, proliferation, angiogenesis and invasion. However, the role of aliphatic acid metabolism genes in bladder cancer patients has not been e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433665/ https://www.ncbi.nlm.nih.gov/pubmed/36059672 http://dx.doi.org/10.3389/fonc.2022.930038 |
_version_ | 1784780671725600768 |
---|---|
author | Song, Tianbao He, Kaixiang Ning, Jinzhuo Li, Wei Xu, Tao Yu, Weimin Rao, Ting Cheng, Fan |
author_facet | Song, Tianbao He, Kaixiang Ning, Jinzhuo Li, Wei Xu, Tao Yu, Weimin Rao, Ting Cheng, Fan |
author_sort | Song, Tianbao |
collection | PubMed |
description | Urothelial bladder cancer (BLCA) is a common internal malignancy with a poor prognosis. The re-programming of lipid metabolism is necessary for cancer cell growth, proliferation, angiogenesis and invasion. However, the role of aliphatic acid metabolism genes in bladder cancer patients has not been explored. The samples’ gene expression and clinicopathological data were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Univariate, multivariate, and LASSO Cox regression were used to develop a BLCA prognostic model. GSVA was used to assess function, whereas pRRophetic was used to assess chemotherapeutic drug sensitivity. The twelve-gene signature may define the tumor immune milieu, according to the risk score model. We compared the expression of aliphatic acid metabolism genes in malignant and non-cancerous tissues and chose 90 with a false discovery rate of 0.05 for The Cancer Genome Atlas cohort. The prognostic risk score model can effectively predict BLCA OS. A nomogram including age, clinical T stage, gender, grade, pathological stage, and clinical M stage was developed as an independent BLCA prognostic predictor. The halfmaximal inhibitory concentration (IC50) was used to assess chemotherapeutic medication response. Sorafenib and Pyrimethamine were used to treat patients with low risk scores more sensitively than patients with high risk scores. Immunotherapy candidates with CMS1 exhibited higher risk ratings. The aliphatic acid prognostic risk score model can assess metabolic trends. Clinical stage and molecular subtype may be used to categorize individuals using the risk score.With this new paradigm, future cancer treatment and immunotherapy may be tailored to the patient’s exact requirements. |
format | Online Article Text |
id | pubmed-9433665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94336652022-09-02 Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment Song, Tianbao He, Kaixiang Ning, Jinzhuo Li, Wei Xu, Tao Yu, Weimin Rao, Ting Cheng, Fan Front Oncol Oncology Urothelial bladder cancer (BLCA) is a common internal malignancy with a poor prognosis. The re-programming of lipid metabolism is necessary for cancer cell growth, proliferation, angiogenesis and invasion. However, the role of aliphatic acid metabolism genes in bladder cancer patients has not been explored. The samples’ gene expression and clinicopathological data were obtained from the Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Univariate, multivariate, and LASSO Cox regression were used to develop a BLCA prognostic model. GSVA was used to assess function, whereas pRRophetic was used to assess chemotherapeutic drug sensitivity. The twelve-gene signature may define the tumor immune milieu, according to the risk score model. We compared the expression of aliphatic acid metabolism genes in malignant and non-cancerous tissues and chose 90 with a false discovery rate of 0.05 for The Cancer Genome Atlas cohort. The prognostic risk score model can effectively predict BLCA OS. A nomogram including age, clinical T stage, gender, grade, pathological stage, and clinical M stage was developed as an independent BLCA prognostic predictor. The halfmaximal inhibitory concentration (IC50) was used to assess chemotherapeutic medication response. Sorafenib and Pyrimethamine were used to treat patients with low risk scores more sensitively than patients with high risk scores. Immunotherapy candidates with CMS1 exhibited higher risk ratings. The aliphatic acid prognostic risk score model can assess metabolic trends. Clinical stage and molecular subtype may be used to categorize individuals using the risk score.With this new paradigm, future cancer treatment and immunotherapy may be tailored to the patient’s exact requirements. Frontiers Media S.A. 2022-08-18 /pmc/articles/PMC9433665/ /pubmed/36059672 http://dx.doi.org/10.3389/fonc.2022.930038 Text en Copyright © 2022 Song, He, Ning, Li, Xu, Yu, Rao and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Song, Tianbao He, Kaixiang Ning, Jinzhuo Li, Wei Xu, Tao Yu, Weimin Rao, Ting Cheng, Fan Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title | Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title_full | Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title_fullStr | Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title_full_unstemmed | Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title_short | Evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
title_sort | evaluation of aliphatic acid metabolism in bladder cancer with the goal of guiding therapeutic treatment |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433665/ https://www.ncbi.nlm.nih.gov/pubmed/36059672 http://dx.doi.org/10.3389/fonc.2022.930038 |
work_keys_str_mv | AT songtianbao evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT hekaixiang evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT ningjinzhuo evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT liwei evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT xutao evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT yuweimin evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT raoting evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment AT chengfan evaluationofaliphaticacidmetabolisminbladdercancerwiththegoalofguidingtherapeutictreatment |